Beste apotheek van Nederland

the second study, prolonged erection appeared more common in the participants treated with
PGE 1 (3.3 versus 10 percent)
Efficacy. In the first trial, 85.3 percent of the participants treated with PGE 1 reported
improved erections versus 60.7 percent of the moxisylate-treated participants. 262 In the second
trial, the rates of improved erection in PGE 1 and moxisylate groups were 40 percent and. 6.7
percent, respectively. 293
PGE 1 versus sodium nitroprusside. One trial compared the efficacy and harms of PGE1
with three different doses of nitroprusside (100µg, 300µg, or 400µg). 278
Harms. In total, 6.7 percent of the participants in PGE 1 group reported pain during injection
versus 0 percent of those in each of the nitroprusside group. About 4.0 percent of the participants
treated with PGE 1 reported dizziness versus 10, 8 and 3 percent for each of the nitroprusside
groups(100µg, 300µg, and 400µg, respectively).
Efficacy. In total, 20 percent of the participants treated with PGE 1 reported full rigidity.
Nitroprusside 100µg was reported to be ineffective in producing erections. In the 300µg and
400µg nitroprusside groups, 15 percent and 14.3 percent of the participants, respectively had full
rigidity.
PGE 1 versus linsidomine. Three trials compared the efficacy and harms of PGE1 to
linsidomine. 273,279,284
Harms. In one trial, 17.5 percent of participants receiving PGE 1 reported penile pain. Similar
data for the linsidomine-treated subjects was not provided. In the linsidomine group, moderate to
severe headache was reported by 7.5 percent of the subjects. 284 In a second trial, 7.5 percent of
PGE 1 participants reported pain during injection versus 2.5 percent of linsidomine subjects. 273
Efficacy. Between 30 and 65 percent of the participants treated with PGE 1 had improved
erections compared with 7.5–12.5 percent of those treated with linsidomine.
PGE 1 versus linsidomine plus urapidil. One trial compared the efficacy and harms of
PGE1 to linsidomine plus urapidil. 273
Efficacy. In total, 40 percent of participants randomly assigned to PGE 1 therapy reported
improved erections versus 25 percent of those randomly assigned to linsidomine plus urapidil
therapy.
Harms. In total, 7.5 percent of participants in each treatment group reported pain during
injection, while 0 percent of those receiving PGE 1 and 12.5 percent of those receiving
linsidomine plus urapidil reported severe hypotension.
PGE 1 versus PGE 1 plus lidocaine. One trial compared the efficacy and harms of PGE1
injections with or without lidocaine.
Harms. The proportions of participants reporting pain in PGE 1 plus lidocaine versus PGE 1
only groups were 45.4 percent and 86.4 percent, respectively.
Efficacy. In total 63.6 percent of the participants allocated to PGE 1 plus lidocaine reported
improved erections versus 27.3 percent of those allocated to PGE 1 alone.
PGE 1 versus PGE 1 plus procaine. One trial compared the efficacy and harms of PGE1
injections with and without procaine (10mg or 20mg). 280
Harms. Of participants allocated to PGE 1 plus procaine, 62.5 percent reported moderate to
severe pain compared with 83.3 percent of those allocated to treatment with PGE 1 only. The
occurrence of severe pain was reported by 16.6 percent versus 45.8 percent of the participants,
respectively.
Efficacy. In total, 66.7 percent of those assigned to receive PGE 1 plus procaine reported
improved erections versus 66.7 percent of those assigned to receive PGE 1 only.
76